Marijke Stigter-van Walsum

5PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursTumour immunologyGlycoconjugates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 26, 2024
Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for Treatment Investigation.

Leon J Wils, Marijke Buijze, Marijke Stigter-van Walsum

|Feb 29, 2024
Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell carcinoma.

Reinout H de Roest, Marijke Stigter van Walsum, Karlijn van der Schilden

|Oct 13, 2023
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.

Jantine E Bakema, Marijke Stigter-van Walsum, Jeffrey R Harris

|Oct 23, 2021
NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.

Mandy Gruijs, Sonja H Ganzevles, Marijke Stigter-van Walsum

|Sep 15, 2019
The human cytomegalovirus-encoded G protein-coupled receptor UL33 exhibits oncomodulatory properties.

Jeffrey R van Senten, Maarten P Bebelman, Tian Shu Fan

Pageof 1

Frequent Collaborators

2 joint publications

Ruud H Brakenhoff

2 joint publications

Rieneke van de Ven

2 joint publications

Elisabeth Bloemena

1 joint publications

Nick D Bergkamp